IP Library › Granted Patent US 11,326,185
Granted Patent B2
US 11,326,185 · App. 16/176,525 · Granted May 10, 2022

Site-specific integration

Inventors: James Rance (Thame, GB); Robert Young (London, GB); Michael J. Agostino (Andover, MA); Mark Moffat (St. Louis, MO); Lin Zhang (Boxford, MA); Baohong Zhang (Madison, CT)
Assignees: LONZA BIOLOGICS PLC; PFIZER INC.
C12N15/907C07K16/00C12N15/10C12N15/90C12P21/00C07K2317/14C07K2317/24C12N2800/22C12N2800/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,326,185
App. No.
16/176,525
Granted
May 10, 2022
Kind
B2
Abstract

The present invention relates to stable and high-producing site-specific integration (SSI) host cells, e. g. Chinese hamster ovary (CHO)-derived host cells, methods to produce and to use them.

Claims (15)

1. A site-specific integration (SSI) host cell comprising:

an endogenous Fer1L4 gene; and

an exogenous nucleotide sequence integrated in said Fer1L4 gene, the exogenous nucleotide sequence comprising at least two recombination target sites,

wherein the exogenous nucleotide sequence is integrated in a region spanning and including exon 28 to exon 40 of the endogenous Fer1L4 gene.

2. The SSI host cell of claim 1 , wherein the exogenous nucleotide sequence comprises a gene coding sequence of interest.

3. The SSI host cell of claim 2 , wherein the at least two recombination target sites flank the gene coding sequence of interest,

wherein an integration site of one of the recombination target sites that flank the gene coding sequence of interest is located between exon 39 and 40 of the endogenous Fer1L4 gene and an integration site of the other recombination target site that flanks the gene coding sequence of interest is located between exon 28 and 29 of the endogenous Fer1L4 gene.

4. The SSI host cell of claim 2 , wherein the gene coding sequence of interest comprises one or more of a gene encoding a selection marker, a detectable protein, an antibody, a peptide antigen, an enzyme, a hormone, a growth factor, a receptor, a fusion protein or other biologically active protein.

5. The SSI host cell of claim 1 , wherein the recombination target site is a FRT site or a lox site.

6. The SSI host cell of claim 4 , wherein the selection marker is a glutamine synthase selection marker, a hygromycin selection marker, a puromycin selection marker or a thymidine kinase selection marker.

7. The SSI host cell of claim 1 , wherein the host cell is a mouse cell, a human cell or a CHO host cell, a CHOK1 host cell or a CHOK1SV host cell.

8. The SSI host cell of claim 3 , wherein the nucleotide sequence of the Fer1L4 gene flanking the integrated exogenous nucleotide sequence is selected from the group consisting of SEQ ID No. 7, 8, 9 and homologous sequences thereof.

9. The SSI host cell of claim 1 , wherein the exogenous nucleotide sequence replaces a portion of the Fer1L4 gene.

10. The SSI host cell of claim 5 , wherein the host cell comprises a FRT site which is a wild type FRT site or a mutant FRT site.

11. The SSI host cell of claim 1 , wherein the recombination target sites comprise at least one wild type FRT site and at least one mutant FRT site.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2018
From: RANCE, JAMES; YOUNG, ROBERT; AGOSTINO, MICHAEL J.; MOFFAT, MARK; ZHANG, LIN; ZHANG, BAOHONG
To: LONZA BIOLOGICS PLC; PFIZER INC.
Reel/Frame 047371/0602 →
Priority Claims (1)
EP 12185330 · Sep 21, 2012 · regional
Continuity (3)
Continuation 14409283
Provisional Application 61663147 · Jun 22, 2012
Related Publication 20190119702A1 · Apr 25, 2019